Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 120

1.

Sustained delivery of a camptothecin prodrug - CZ48 by nanosuspensions with improved pharmacokinetics and enhanced anticancer activity.

Dong D, Hsiao CH, Giovanella BC, Wang Y, Chow DS, Li Z.

Int J Nanomedicine. 2019 May 24;14:3799-3817. doi: 10.2147/IJN.S196453. eCollection 2019.

2.

Desmoplastic small round cell tumor (DSRCT) xenografts and tissue culture lines: Establishment and initial characterization.

Markides CS, Coil DR, Luong LH, Mendoza J, Kozielski T, Vardeman D, Giovanella BC.

Oncol Lett. 2013 May;5(5):1453-1456. Epub 2013 Mar 19.

3.

TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal.

Killela PJ, Reitman ZJ, Jiao Y, Bettegowda C, Agrawal N, Diaz LA Jr, Friedman AH, Friedman H, Gallia GL, Giovanella BC, Grollman AP, He TC, He Y, Hruban RH, Jallo GI, Mandahl N, Meeker AK, Mertens F, Netto GJ, Rasheed BA, Riggins GJ, Rosenquist TA, Schiffman M, Shih IeM, Theodorescu D, Torbenson MS, Velculescu VE, Wang TL, Wentzensen N, Wood LD, Zhang M, McLendon RE, Bigner DD, Kinzler KW, Vogelstein B, Papadopoulos N, Yan H.

Proc Natl Acad Sci U S A. 2013 Apr 9;110(15):6021-6. doi: 10.1073/pnas.1303607110. Epub 2013 Mar 25.

4.

ISG15 as a novel tumor biomarker for drug sensitivity.

Desai SD, Wood LM, Tsai YC, Hsieh TS, Marks JR, Scott GL, Giovanella BC, Liu LF.

Mol Cancer Ther. 2008 Jun;7(6):1430-9. doi: 10.1158/1535-7163.MCT-07-2345.

5.

Establishment and characterization of cancer cell cultures and xenografts derived from primary or metastatic Mullerian cancers.

Verschraegen CF, Hu W, Du Y, Mendoza J, Early J, Deavers M, Freedman RS, Bast RC Jr, Kudelka AP, Kavanagh JJ, Giovanella BC.

Clin Cancer Res. 2003 Feb;9(2):845-52.

6.

Preclinical evaluation of the anticancer activity and toxicity of 9-nitro-20(S)-camptothecin (Rubitecan).

Giovanella BC, Stehlin JS, Hinz HR, Kozielski AJ, Harris NJ, Vardeman DM.

Int J Oncol. 2002 Jan;20(1):81-8.

PMID:
11743646
7.

Dependence of anticancer activity of camptothecins on maintaining their lactone function.

Giovanella BC, Harris N, Mendoza J, Cao Z, Liehr J, Stehlin JS.

Ann N Y Acad Sci. 2000;922:27-35.

PMID:
11193902
8.

Pharmacology of camptothecin esters.

Liehr JG, Harris NJ, Mendoza J, Ahmed AE, Giovanella BC.

Ann N Y Acad Sci. 2000;922:216-23. Review.

PMID:
11193897
9.

Modified lactone/carboxylate salt equilibria in vivo by liposomal delivery of 9-nitro-camptothecin.

Chow DS, Gong L, Wolfe MD, Giovanella BC.

Ann N Y Acad Sci. 2000;922:164-74.

PMID:
11193891
10.

9-Nitrocamptothecin liposome aerosol treatment of human cancer subcutaneous xenografts and pulmonary cancer metastases in mice.

Knight V, Kleinerman ES, Waldrep JC, Giovanella BC, Gilbert BE, Koshkina NV.

Ann N Y Acad Sci. 2000;922:151-63.

PMID:
11193890
11.

Anti-cancer activity of 9-nitrocamptothecin liposome aerosol in mice.

Knight V, Koshkina N, Waldrep C, Giovanella BC, Kleinerman E, Gilbert B.

Trans Am Clin Climatol Assoc. 2000;111:135-45. No abstract available.

12.

Anticancer effect of 9-nitrocamptothecin liposome aerosol on human cancer xenografts in nude mice.

Knight V, Koshkina NV, Waldrep JC, Giovanella BC, Gilbert BE.

Cancer Chemother Pharmacol. 1999;44(3):177-86.

PMID:
10453718
13.

A phase II clinical and pharmacological study of oral 9-nitrocamptothecin in patients with refractory epithelial ovarian, tubal or peritoneal cancer.

Verschraegen CF, Gupta E, Loyer E, Kavanagh JJ, Kudelka AP, Freedman RS, Edwards CL, Harris N, Steger M, Steltz V, Giovanella BC, Stehlin JS.

Anticancer Drugs. 1999 Apr;10(4):375-83.

PMID:
10378672
14.

A study of 9-nitrocamptothecin (RFS-2000) in patients with advanced pancreatic cancer.

Stehlin JS, Giovanella BC, Natelson EA, De Ipolyi PD, Coil D, Davis B, Wolk D, Wallace P, Trojacek A.

Int J Oncol. 1999 May;14(5):821-31.

PMID:
10200331
15.

A phase I clinical and pharmacological study of oral 9-nitrocamptothecin, a novel water-insoluble topoisomerase I inhibitor.

Verschraegen CF, Natelson EA, Giovanella BC, Kavanagh JJ, Kudelka AP, Freedman RS, Edwards CL, Ende K, Stehlin JS.

Anticancer Drugs. 1998 Jan;9(1):36-44.

PMID:
9491790
16.

PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer.

Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, Puc J, Miliaresis C, Rodgers L, McCombie R, Bigner SH, Giovanella BC, Ittmann M, Tycko B, Hibshoosh H, Wigler MH, Parsons R.

Science. 1997 Mar 28;275(5308):1943-7.

17.
18.

Phase I clinical and pharmacological studies of 20-(S)-camptothecin and 20-(S)-9-nitrocamptothecin as anticancer agents.

Natelson EA, Giovanella BC, Verschraegen CF, Fehir KM, De Ipolyi PD, Harris N, Stehlin JS.

Ann N Y Acad Sci. 1996 Dec 13;803:224-30.

PMID:
8993516
19.

Protocols for the treatment of human tumor xenografts with camptothecins.

Giovanella BC, Natelson E, Harris N, Vardeman D, Stehlin JS.

Ann N Y Acad Sci. 1996 Dec 13;803:181-7. Review.

PMID:
8993511
20.

Pharmacokinetics of camptothecins administered orally.

Liehr JG, Ahmed AE, Giovanella BC.

Ann N Y Acad Sci. 1996 Dec 13;803:157-63. Review.

PMID:
8993508
21.

Presence of Mason-Pfizer monkey virus in some stocks of the human HBL-100 mammary epithelial cell line.

Robert-Guroff M, Stern TL, Richardson ES, Giovanella BC, Michaels FH.

J Natl Cancer Inst. 1996 Mar 20;88(6):372-4. No abstract available.

PMID:
8609647
22.

Influence of route of administration on [3H]-camptothecin distribution and tumor uptake in CASE-bearing nude mice: whole-body autoradiographic studies.

Ahmed AE, Jacob S, Giovanella BC, Kozielski AJ, Stehlin JS Jr, Liehr JG.

Cancer Chemother Pharmacol. 1996;39(1-2):122-30.

PMID:
8995509
23.

Growth inhibition of human cancer metastases by camptothecins in newly developed xenograft models.

Potmesil M, Vardeman D, Kozielski AJ, Mendoza J, Stehlin JS, Giovanella BC.

Cancer Res. 1995 Dec 1;55(23):5637-41.

24.

Antitumor effect of liposome-incorporated camptothecin in human malignant xenografts.

Daoud SS, Fetouh MI, Giovanella BC.

Anticancer Drugs. 1995 Feb;6(1):83-93.

PMID:
7756688
25.

Modulation of the response to chemotherapy in a human melanoma clone by the site of growth in the nude mouse.

Verschraegen CF, Mendoza JT, Kozielski AJ, Giovanella BC.

Anticancer Res. 1995 Jan-Feb;15(1):9-11.

PMID:
7733648
26.

Partial characterization of human leukemia U-937 cell sublines resistant to 9-nitrocamptothecin.

Pantazis P, Mendoza JT, DeJesus A, Rubin E, Kufe D, Giovanella BC.

Eur J Haematol. 1994 Sep;53(3):135-44.

PMID:
7925856
27.

Development of resistance to 9-nitro-camptothecin by human leukemia U-937 cells in vitro correlates with altered sensitivities to several anticancer drugs.

Pantazis P, Mendoza J, DeJesus A, Early J, Shaw M, Giovanella BC.

Anticancer Drugs. 1994 Aug;5(4):473-9.

PMID:
7949254
28.
29.

New perspectives in colon cancer chemotherapy.

Giovanella BC.

Dis Colon Rectum. 1994 Feb;37(2 Suppl):S96-9.

PMID:
8313802
30.

Cytotoxic efficacy of 9-nitrocamptothecin in the treatment of human malignant melanoma cells in vitro.

Pantazis P, Early JA, Mendoza JT, DeJesus AR, Giovanella BC.

Cancer Res. 1994 Feb 1;54(3):771-6.

31.

In vitro growth characteristics of embryo fibroblasts isolated from p53-deficient mice.

Harvey M, Sands AT, Weiss RS, Hegi ME, Wiseman RW, Pantazis P, Giovanella BC, Tainsky MA, Bradley A, Donehower LA.

Oncogene. 1993 Sep;8(9):2457-67.

PMID:
8103211
32.
33.

Camptothecin derivatives induce regression of human ovarian carcinomas grown in nude mice and distinguish between non-tumorigenic and tumorigenic cells in vitro.

Pantazis P, Kozielski AJ, Mendoza JT, Early JA, Hinz HR, Giovanella BC.

Int J Cancer. 1993 Mar 12;53(5):863-71.

PMID:
8449612
34.

9-Nitro-camptothecin delays growth of U-937 leukemia tumors in nude mice and is cytotoxic or cytostatic for human myelomonocytic leukemia lines in vitro.

Pantazis P, Mendoza JT, Early JA, Kozielski AJ, Natelson EA, Giovanella BC.

Eur J Haematol. 1993 Feb;50(2):81-9.

PMID:
8440362
35.

Efficacy of camptothecin congeners in the treatment of human breast carcinoma xenografts.

Pantazis P, Kozielski AJ, Vardeman DM, Petry ER, Giovanella BC.

Oncol Res. 1993;5(8):273-81.

PMID:
8012059
36.

An experimental model for the study of thermochemotherapy in vivo.

Coil DR, Giovanella BC, Greeff PJ, Stehlin JS, Davis BR.

Anticancer Res. 1992 Sep-Oct;12(5):1363-71.

PMID:
1444192
37.

Complete inhibition of growth followed by death of human malignant melanoma cells in vitro and regression of human melanoma xenografts in immunodeficient mice induced by camptothecins.

Pantazis P, Hinz HR, Mendoza JT, Kozielski AJ, Williams LJ Jr, Stehlin JS Jr, Giovanella BC.

Cancer Res. 1992 Jul 15;52(14):3980-7.

38.

Complete growth inhibition of human cancer xenografts in nude mice by treatment with 20-(S)-camptothecin.

Giovanella BC, Hinz HR, Kozielski AJ, Stehlin JS Jr, Silber R, Potmesil M.

Cancer Res. 1991 Jun 1;51(11):3052-5.

39.

Specific organ metastases of human melanoma cells injected into the arterial circulation of nude mice.

Verschraegen CF, Giovanella BC, Mendoza JT, Kozielski AJ, Stehlin JS Jr.

Anticancer Res. 1991 Mar-Apr;11(2):529-35.

PMID:
2064308
40.

Tumorigenic transformation of spontaneously immortalized fibroblasts from patients with a familial cancer syndrome.

Bischoff FZ, Strong LC, Yim SO, Pratt DR, Siciliano MJ, Giovanella BC, Tainsky MA.

Oncogene. 1991 Feb;6(2):183-6.

PMID:
2000218
41.

Heterotransplantation of human breast carcinomas in nude mice. Correlation between successful heterotransplants, poor prognosis and amplification of the HER-2/neu oncogene.

Giovanella BC, Vardeman DM, Williams LJ, Taylor DJ, de Ipolyi PD, Greeff PJ, Stehlin JS, Ullrich A, Cailleau R, Slamon DJ, et al.

Int J Cancer. 1991 Jan 2;47(1):66-71.

PMID:
1985881
42.

Spontaneous abnormalities in normal fibroblasts from patients with Li-Fraumeni cancer syndrome: aneuploidy and immortalization.

Bischoff FZ, Yim SO, Pathak S, Grant G, Siciliano MJ, Giovanella BC, Strong LC, Tainsky MA.

Cancer Res. 1990 Dec 15;50(24):7979-84.

43.

Consistent karyotypic abnormalities in human malignant melanomas.

Kacker RK, Giovanella BC, Pathak S.

Anticancer Res. 1990 Jul-Aug;10(4):859-71.

PMID:
2382982
44.

Susceptibility for N-ras-mediated transformation requires loss of tumor suppressor activity.

Krizman DB, Giovanella BC, Tainsky MA.

Somat Cell Mol Genet. 1990 Jan;16(1):15-27.

PMID:
2408157
45.

Cytogenetic characterization of two human milk-derived cell line (HBL-100) passages differing in tumorigenicity.

Dhaliwal MK, Giovanella BC, Pathak S.

Anticancer Res. 1990 Jan-Feb;10(1):113-7.

PMID:
2334116
46.

Heat shock proteins.

Giovanella BC.

Adv Exp Med Biol. 1990;267:95-8. Review. No abstract available.

PMID:
2088074
47.

DNA topoisomerase I--targeted chemotherapy of human colon cancer in xenografts.

Giovanella BC, Stehlin JS, Wall ME, Wani MC, Nicholas AW, Liu LF, Silber R, Potmesil M.

Science. 1989 Nov 24;246(4933):1046-8.

PMID:
2555920
48.

Multiple karyotypic abnormalities, including structural rearrangements of 11p, in cell lines from malignant melanomas.

Heim S, Mandahl N, Arheden K, Giovanella BC, Yim SO, Stehlin JS Jr, Mitelman F.

Cancer Genet Cytogenet. 1988 Oct 1;35(1):5-20.

PMID:
3180009
49.

PA-1, a human cell model for multistage carcinogenesis: oncogenes and other factors.

Tainsky MA, Krizman DB, Chiao PJ, Yim SO, Giovanella BC.

Anticancer Res. 1988 Sep-Oct;8(5A):899-913. Review.

PMID:
3052262
50.

Characterization of the 31P nuclear magnetic resonance spectrum from human melanoma tumors implanted in nude mice.

Corbett RJ, Nunnally RL, Giovanella BC, Antich PP.

Cancer Res. 1987 Oct 1;47(19):5065-9.

Supplemental Content

Loading ...
Support Center